pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 14·1 min read
save

AstraZeneca follows Merck with Phase 3 win in bladder cancer

A combination of AstraZeneca's Imfinzi with Pfizer and Astellas’ Padcev kept more bladder cancer patients alive than standard of care, the company said Thursday. AstraZeneca said it would seek approval for the combination, but it ...

May 14, 2026·read at Endpoints ↗

May 14, 2026 10:31 AM EDT R&D As­traZeneca fol­lows Mer­ck with Phase 3 win in blad­der can­cer Elizabeth Cairns Senior biopharma journalist A com­bi­na­tion of As­traZeneca’s Imfinzi with Pfiz­er and Astel­las’ Pad­cev kept more blad­der can­cer pa­tients alive than stan­dard of care, the com­pa­ny said Thurs­day. As­traZeneca … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
82 words · retrieved May 14
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ASTRAZENECA3ASTELLASPFIZER
drugs
durvalumab2PADCEVenfortumab vedotin
topics
Oncology2Approval

related stories

  • May 15Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workersBioPharma Dive
  • Jul 13Agenus surges on study pivot; Apnimed lines up an IPOBioPharma Dive
  • Aug 5Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launchBioPharma Dive
  • Jul 21‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx dealFierce Biotech
  • May 12GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026onclive